Rationaler for behandling med januskinase 1/2-hæmning af svært syge patienter med COVID-19-pneumoni
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.
Bidragets oversatte titel | Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia |
---|---|
Originalsprog | Dansk |
Artikelnummer | V04200234 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 182 |
Udgave nummer | 25 |
Antal sider | 9 |
ISSN | 0041-5782 |
Status | Udgivet - 2020 |
- Betacoronavirus, COVID-19, Coronavirus Infections/drug therapy, Humans, Janus Kinase Inhibitors/therapeutic use, Lymphohistiocytosis, Hemophagocytic/drug therapy, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2
Forskningsområder
Links
- https://ugeskriftet.dk/files/scientific_article_files/2020-06/v04200234_web.pdf
Forlagets udgivne version
ID: 269690725